Adbry (Tralokinumab-Ldrm) Patent Expiration, LOE Window & CMS Spending

Adbry (Tralokinumab-Ldrm) by Leo As: Biologic BLA (Purple Book Regime), 0 AB generics, $91.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLeo As
FDA Application & PathwayB761180 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$91.5M
2024 Medicare Part D Spend$49.5M
2024 Medicaid Spend$41.9M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 21.5% 2-yr change)